Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.


PARTNER
Receptor.AI
 
UPACC
P13716

UPID:
HEM2_HUMAN

ALTERNATIVE NAMES:
Porphobilinogen synthase

ALTERNATIVE UPACC:
P13716; A8K375; B2R6F2; Q16870; Q16871; Q9BVQ9

BACKGROUND:
The enzyme Delta-aminolevulinic acid dehydratase, known alternatively as Porphobilinogen synthase, is pivotal in the early steps of tetrapyrrole biosynthesis. By binding and condensing two 5-aminolevulinate molecules, it initiates the production of porphobilinogen, a critical precursor in heme and chlorophyll synthesis.

THERAPEUTIC SIGNIFICANCE:
Linked to Acute hepatic porphyria, a condition marked by severe abdominal pain and neurological issues, this enzyme's genetic variants underscore its importance. Exploring the enzyme's role could unveil new therapeutic strategies for managing this and related porphyrias.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.